← Leaderboards
Michael M Altaweel
University Of Wisconsin Madison
$4,628,844
Attributed
$4,628,844
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $484.6K · FY2005–22$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,628,844 · 3
By mechanism
U10$3,348,668 · 2
UG1$1,280,176 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Ronald Klein$10,952,330
- Michael S Ip$11,543,058
- Matthew D Davis$3,872,794
- Barbara A Blodi$5,082,053
Others in their field
Top investigators on “Implant”
- Myron S Cohen · Family Health International$91,263,426
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Janet T. Holbrook · Johns Hopkins University$44,705,350
- Keri Hammel · The Emmes Company, Llc$39,666,467
- Richard A Andersen · California Institute Of Technology$29,741,172
- Robert Jay Greenberg · Second Sight Medical Products, Inc.$28,210,284
Research focus
ImplantUveitisReadingWisconsinProtocols DocumentationSteroidsMacular EdemaImageReportingTrainingUniversitiesTreatment TrialResearch PersonnelFundusAdrenal Cortex HormonesCollaborationsBlindnessLeadershipMonitorPrincipal InvestigatorOptical Coherence TomographyRetinalEvaluationPublications
Grant awards (21)
ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial$282,710
UG1 · FY2022 · EY · contact PI
ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial$282,710
UG1 · FY2021 · EY · contact PI
ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial$282,709
UG1 · FY2020 · EY · contact PI
ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial$282,709
UG1 · FY2019 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$272,569
U10 · FY2018 · EY · contact PI
ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial$149,338
UG1 · FY2018 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$267,406
U10 · FY2017 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$211,364
U10 · FY2016 · EY · contact PI
MUST Competitive Renewal$212,384
U10 · FY2015 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$200,962
U10 · FY2015 · EY · contact PI
MUST Competitive Renewal$212,384
U10 · FY2014 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$160,166
U10 · FY2014 · EY · contact PI
MUST Competitive Renewal$212,384
U10 · FY2013 · EY · contact PI
MUST Competitive Renewal$183,844
U10 · FY2012 · EY · contact PI
MUST Competitive Renewal$28,540
U10 · FY2012 · EY · contact PI
Reading Center: Multicenter Uveitis Steroid Trial$484,596
U10 · FY2009 · EY · contact PI
Reading Center: Multicenter Uveitis Steroid Trial$235,099
U10 · FY2008 · EY · contact PI
Reading Center: Multicenter Uveitis Steroid Trial$175,213
U10 · FY2007 · EY · contact PI
Reading Center: Multicenter Uveitis Steroid Trial$191,042
U10 · FY2006 · EY · contact PI
Reading Center: Multicenter Uveitis Steroid Trial$112,019
U10 · FY2005 · EY
Reading Center: Multicenter Uveitis Steroid Trial$188,696
U10 · FY2004 · EY